According to new clinical presented at the recent American College of Gastroenterology (ACG) Annual Scientific Meeting in Las Vegas, Zelnorm® (tegaserod maleate) demonstrated potential in the treatment of the multiple symptoms of dysmotility-type dyspepsia.
Currently, there are no prescription medications approved to treat dysmotility-type dyspepsia (or the symptoms associated with this condition), a common digestive condition characterized by discomfort and bloating that occurs in the abdominal area.
Discovered and developed by Novartis (NYSE: NVS), Zelnorm® is the first in a novel class of drugs that act as an agonist at 5HT4 (serotonin type 4) receptors, it mimics the natural effects of serotonin by activating 5HT4 receptors, which normalizes impaired motility in the GI tract, thereby inhibits visceral sensitivity and stimulating intestinal secretion.
Find more details from the press release (a pdf file).
Comment Preview